CTRI/2019/09/021315已完成4 期
An Open Labeled Single Group Proof-of-concept study to evaluate the Efficacy & Safety of ASTHIPOSHAKA VATI in patients suffering from ASTHIKSHAYA (Osteopenia)
Shri Dhootapapeshwar Limited Mumbai0 个研究点目标入组 36 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients of either sex between the age group of 40-75 years (both years inclusive)
- •2.Patients suffering from ASTHIKSHAYA (Osteopenia) with BMD T- score between (-1 to -2.5)
- •3.Those with a history of fractures that may have occurred with a minor injury or fall
- •4.Ready to abide by trial procedures and to give informed consent
排除标准
- •1.Patients who are consuming any drug which is known to affect bone metabolism for e.g. SERMs, bisphosphonates, calcitonin, Vit.D (more than 60,000 units) and corticosteroids (more than 5mg/day of prednisolone or equivalent) for more than 3 months, methotrexate, anti- convulsants, diuretics, etc.
- •2.Patients whose Serum Ca++ level < 2.2 or > 2.6 mmol/L ( < 9 or >10.5 mg/dL)
- •3.Patient suffering from Osteomalacia, Tumor, Osteonecrosis, Infection, and other bone-softening metabolic disorders.
- •4.Patients suffering from congenital disorders (Dysosteogenesis and Marfanâ??s Syndrome)
- •5.Patients with Leukemia, Lymphoma, Metastases (bony and other), Pathologic fractures secondary to bone metastases from cancer, Pediatric osteogenesis imperfect or Renal osteodystrophy, Malabsorption syndrome
- •6.Patients with endocrine disorders (Hyperthyroidism, hyperparathyroidism, Untreated Cushingâ??s syndrome)
- •7.Patients who have undergone Organ transplantation
- •8.Patients who are immobilized since > 6 weeks
- •9.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
- •10.Patients with poorly controlled Hypertension ( > 160 / 100 mm Hg)
- •11.Any other serious illness e.g. Hepatic/renal failure.
- •12.Patient receiving any other method of treatment.
- •13.Patients requiring long term treatment of oral and/or injectable steroids or surgical intervention.
- •14.Symptomatic patient with clinical evidence of Heart failure.
- •15.Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT > 3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.2mg/dl), uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or other concurrent severe disease.
- •16.Patients with poorly controlled Diabetes Mellitus (HbA1c > 10%)
- •17.Alcoholics and/or drug abusers.
- •18.Pregnant and lactating women,
- •19.H/o hypersensitivity to any of the trial drugs or their ingredients
- •20.Patients who have completed participation in any other clinical trial during the past six (06) months.
- •21.Any other condition which the P.I. thinks may jeopardize the study.
研究者
相似试验
尚未招募
2 期
Effect of Myostaal SB Tablets in Participants Suffering with OsteopeniaCTRI/2021/06/034249Solumiks Herbaceuticals Limited
已完成
4 期
se of Arshkeyt in Anal FissureCTRI/2020/11/029129Solumiks Herbaceuticals Limited36
已完成
不适用
A proof of concept clinical study to assess the efficacy and safety of VENTIPEEP in stabilizing the Oxygen levels in patients with ARDSCTRI/2021/03/032184Flextool equipment pvtltd50
招募中
2 期
Medical device clinical trial on Covid 19 patients.CTRI/2021/06/034470StanwixForbes LLC
已完成
2 期
AN OPEN-LABEL, SINGLE-ARM, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE AND MULTIPLE DOSES OF REGN1500 IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAhereditary abnormal high cholesterol level1008362410013317homozygous familial hypercholesterolemiaNL-OMON43236Regeneron Pharmaceuticals, Inc.2